#QUEST-2

The FDA has approved Olysio (simeprevir) to treat those with genotype 1 of hepatitis C who have compensated liver disease, including...

A recent liver conference made it more clear than ever that the means to blow hepatitis C off the map is just within reach.

Simeprevir demonstrated greater efficacy than the current line of hepatitis C drugs among those with genotype and who had compensated liver d...

Janssen’s investigational hepatitis C drug simeprevir received a unanimous recommendation for approval from a U.S. FDA panel.

The FDA has given Janssen Research and Development priority review status for its investigational hepatitis C therapy simeprevir.

Janssen has submitted its investigational agent simeprevir to the U.S. Food and Drug Administration for approval for treatment of genotype.

Adding Janssen Therapeutics’ TMC435, a once-daily experimental hepatitis C virus (HCV) protease inhibitor, to pegylated interferon and ribavir...